


## Claims

## 1. Compounds of Formula (I)



5

wherein

A is a heteroalkyl-, heterocycloalkyl-, heteroalkylcycloalkyl-, heteroaryl- or heteroarylalkyl-group,

10

U is hydrogen, halogen, an alkyl, heteroalkyl-, heterocycloalkyl-, heteroalkylcycloalkyl-, heteroaryl- or heteroarylalkyl-group,

15

G-E is selected from the following groups,



wherein R' is F or a C<sub>1</sub>-C<sub>3</sub> alkyl group or G-E is part of an optionally substituted phenyl ring,

20

R<sup>1</sup> is a C<sub>1</sub>-C<sub>4</sub>-alkyl-, a C<sub>1</sub>-C<sub>4</sub>-alkenyl-, a C<sub>1</sub>-C<sub>4</sub>-alkynyl- or a C<sub>3</sub>-C<sub>4</sub>-cycloalkyl-group,

L-V-W is a group of formula CH=CH-CH, CH<sub>2</sub>-CH<sub>2</sub>-CH or CH<sub>2</sub>-CH=C, wherein the double bonds may be cis or trans isomers,

5 n is 0 or 2,



X is oxygen or a group of the formula NR<sup>2</sup>, wherein R<sup>2</sup> is hydrogen, an alkyl-, alkenyl-, alkynyl-, heteroalkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcycloalkyl-, heteroalkylcycloalkyl-, heterocycloalkyl-, aralkyl- or heteroarylalkyl-group and

10 R<sup>3</sup> and R<sup>4</sup> independently from each other represent hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl or together are part of a cyclo-  
15 alkyl group with 3 or 4 ring atoms,

or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.

20 2. Compounds according to claim 1, wherein A is a group of the formula -C(CH<sub>3</sub>)=CHR<sup>5</sup> or -CH=CHR<sup>5</sup>, wherein R<sup>5</sup> is a heteroaryl- or a heteroarylalkyl group.

25 3. Compounds according to claim 1, wherein A is a group of formula (II) or (III)



wherein Q is sulphur, oxygen or NR<sup>7</sup>, wherein R<sup>7</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>4</sub> heteroalkyl, z is Nitrogen or CH and R<sup>6</sup> is OR<sup>8</sup>, NHR<sup>8</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkenyl, C<sub>1</sub>-C<sub>4</sub> alkynyl or C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>4</sub> heteroalkyl.

5 4. Compounds according to any one of the preceding claims, wherein X is oxygen or NH.

10 5. Compounds according to any one of the preceding claims, wherein R<sup>1</sup> is methyl or ethyl.

6. Compounds according to any one of the preceding claims, wherein R<sup>3</sup> and R<sup>4</sup> are methyl groups.

15 7. Compounds according to any one of the preceding claims, wherein U is hydrogen, fluorine, methyl, trifluoromethyl or COOH.

20 8. Compounds according to claim 3, wherein z is CH and Q is sulphur or oxygen.

9. Compounds according to claim 3, wherein R<sup>6</sup> is methyl, CH<sub>2</sub>OH or CH<sub>2</sub>NH<sub>2</sub>.

25 10. Pharmaceutical compositions containing a compound, a pharmacologically acceptable salt, a solvate, a hydrate or a prodrug according to any one of the preceding claims and optionally carriers and/or adjuvants and/or diluents.

30

11. Use of a compound or a pharmaceutical composition according to any one of the preceding claims for the manufacture of a medicament for the treatment of cancer.